IL137019A0 - Azolo triazines and pyrimidines - Google Patents

Azolo triazines and pyrimidines

Info

Publication number
IL137019A0
IL137019A0 IL13701999A IL13701999A IL137019A0 IL 137019 A0 IL137019 A0 IL 137019A0 IL 13701999 A IL13701999 A IL 13701999A IL 13701999 A IL13701999 A IL 13701999A IL 137019 A0 IL137019 A0 IL 137019A0
Authority
IL
Israel
Prior art keywords
pyrimidines
azolo
triazines
azolo triazines
crf
Prior art date
Application number
IL13701999A
Other languages
English (en)
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/014,734 external-priority patent/US6313124B1/en
Priority claimed from US09/015,002 external-priority patent/US6191131B1/en
Priority claimed from US09/015,001 external-priority patent/US6060478A/en
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of IL137019A0 publication Critical patent/IL137019A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
IL13701999A 1998-01-28 1999-01-28 Azolo triazines and pyrimidines IL137019A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/014,734 US6313124B1 (en) 1997-07-23 1998-01-28 Tetrazine bicyclic compounds
US09/015,002 US6191131B1 (en) 1997-07-23 1998-01-28 Azolo triazines and pyrimidines
US09/015,001 US6060478A (en) 1996-07-24 1998-01-28 Azolo triazines and pyrimidines
PCT/US1999/001824 WO1999038868A1 (en) 1998-01-28 1999-01-28 Azolo triazines and pyrimidines

Publications (1)

Publication Number Publication Date
IL137019A0 true IL137019A0 (en) 2001-06-14

Family

ID=27360164

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13701999A IL137019A0 (en) 1998-01-28 1999-01-28 Azolo triazines and pyrimidines

Country Status (19)

Country Link
EP (2) EP1049699B1 (sl)
JP (1) JP4228332B2 (sl)
KR (1) KR100574313B1 (sl)
CN (2) CN1137123C (sl)
AT (2) ATE264860T1 (sl)
AU (1) AU748818C (sl)
BR (1) BR9908206A (sl)
CA (2) CA2314613C (sl)
DE (2) DE69926665T2 (sl)
DK (2) DK1344779T3 (sl)
ES (2) ES2247478T3 (sl)
IL (1) IL137019A0 (sl)
NZ (2) NZ505079A (sl)
PL (1) PL200939B1 (sl)
PT (2) PT1049699E (sl)
SG (1) SG111076A1 (sl)
SI (2) SI1344779T1 (sl)
TW (1) TW520372B (sl)
WO (1) WO1999038868A1 (sl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4331500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolotriazines as crf antagonists
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
EP1224187B1 (en) 1999-09-30 2006-02-22 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
YU23802A (sh) 1999-09-30 2004-09-03 Neurogen Corporation Određeni alkilen diamin-supstituisani pirazolo/1,5-a/-1,5- piramidini i pirazolo/1,5-a/1,3,5-triazini
US6525067B1 (en) 1999-11-23 2003-02-25 Pfizer Inc Substituted heterocyclic derivatives
AU2001263329A1 (en) 2000-05-18 2001-11-26 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods relating thereto
NZ524348A (en) * 2000-08-02 2004-07-30 Malope Company Ltd Diagnosis and treatment of non-ulcer dyspepsia based on dysfunction in the corticotropin releasing hormone (CRH) receptor and repsonse to ACTH
DK1368094T3 (da) * 2001-03-13 2007-07-02 Bristol Myers Squibb Pharma Co 4-(2-Butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)-pyrazolo[1,5-a]-1,3,5-triazin, dens enantiomerer og farmaceutisk acceptable salte som corticotropin-frigivende faktor-receptor- ligander
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
US7056920B2 (en) * 2003-04-04 2006-06-06 Pfizer Inc Pyrrolo[1,2-B]pyridazine compounds and their uses
US7034023B2 (en) * 2003-04-04 2006-04-25 Pfizer Inc Pyrrolo[1,2-B]pyridazine compounds and their uses
KR20070009537A (ko) * 2003-12-22 2007-01-18 에스비 팜코 푸에르토 리코 인크. Ｃｒｆ 수용체 길항제 및 그와 관련된 방법
EP1697369A1 (en) * 2003-12-22 2006-09-06 SB Pharmco Puerto Rico Inc Crf receptor antagonists and methods relating thereto
JP2008503444A (ja) * 2004-02-13 2008-02-07 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド Ｃｒｆ受容体アンタゴニスト、その調製法、その医薬組成物およびその使用
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
US7851468B2 (en) * 2006-05-15 2010-12-14 Cephalon, Inc. Substituted pyrazolo[3,4-d]pyrimidines
WO2007149938A2 (en) 2006-06-21 2007-12-27 The Salk Institute Biological Studies Methods for promoting hair growth
US8895745B2 (en) 2006-12-22 2014-11-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as FGFR inhibitors
CA2672213C (en) 2006-12-22 2016-02-16 Astex Therapeutics Limited Bicyclic amine derivatives as protein tyrosine kinase inhibitors
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN104876935B (zh) * 2015-05-18 2017-04-19 南方医科大学 2‑氨基吡咯并[1,2‑f][1,2,4]三嗪类化合物、合成方法及应用
BR112017026061B1 (pt) * 2015-06-24 2023-03-28 Curovir Ab Composto, composição farmacêutica, e, uso de um composto
CN110996943A (zh) 2017-08-14 2020-04-10 云杉生物科学公司 促肾上腺皮质激素释放因子受体拮抗剂
US20210137935A1 (en) * 2017-08-14 2021-05-13 Spruce Biosciences, Inc. Corticotropin releasing factor receptor antagonists
CN112479956A (zh) * 2019-07-30 2021-03-12 杭州阿诺生物医药科技有限公司 一种用于制备腺苷受体抑制剂中间体的方法
KR20230043222A (ko) 2020-08-12 2023-03-30 스프루스 바이오사이언시스 인코포레이티드 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
CA2194756A1 (en) * 1995-05-12 1996-11-14 Jun Yuan Novel deazapurine derivatives; a new class of crf1 specific ligands
EP0880523B1 (en) * 1996-02-07 2006-08-16 Neurocrine Biosciences, Inc. Pyrazolopyrimidines as crf receptor antagonists
EP0915880B1 (en) * 1996-07-24 2007-10-10 Bristol-Myers Squibb Pharma Company Azolo triazines and pyrimidines
EP0923582B1 (en) * 1996-08-28 2006-09-20 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives

Also Published As

Publication number Publication date
EP1344779B1 (en) 2005-08-10
NZ505079A (en) 2003-08-29
SI1344779T1 (sl) 2006-02-28
CA2314613A1 (en) 1999-08-05
JP2002501922A (ja) 2002-01-22
CN1137123C (zh) 2004-02-04
CN1542010A (zh) 2004-11-03
BR9908206A (pt) 2000-12-05
DE69916578T2 (de) 2005-03-31
PT1049699E (pt) 2004-08-31
DE69916578D1 (de) 2004-05-27
CA2614603A1 (en) 1999-08-05
KR100574313B1 (ko) 2006-04-27
EP1049699B1 (en) 2004-04-21
PT1344779E (pt) 2005-10-31
EP1049699A1 (en) 2000-11-08
ES2247478T3 (es) 2006-03-01
DK1344779T3 (da) 2005-09-05
KR20010040426A (ko) 2001-05-15
ATE264860T1 (de) 2004-05-15
PL200939B1 (pl) 2009-02-27
JP4228332B2 (ja) 2009-02-25
SI1049699T1 (sl) 2004-10-31
CA2614603C (en) 2011-08-16
PL342183A1 (en) 2001-05-21
EP1344779A1 (en) 2003-09-17
ATE301657T1 (de) 2005-08-15
AU748818B2 (en) 2002-06-13
AU2478799A (en) 1999-08-16
DK1049699T3 (da) 2004-07-05
DE69926665T2 (de) 2006-06-08
AU748818C (en) 2003-11-20
HK1060348A1 (en) 2004-08-06
NZ524842A (en) 2003-10-31
WO1999038868A1 (en) 1999-08-05
CA2314613C (en) 2009-12-08
SG111076A1 (en) 2005-05-30
ES2218991T3 (es) 2004-11-16
DE69926665D1 (de) 2005-09-15
CN1289335A (zh) 2001-03-28
TW520372B (en) 2003-02-11

Similar Documents

Publication Publication Date Title
SG111076A1 (en) Azolo triazines and pyrimidines
LV12292A (lv) Triazinu un pirimidinu azoloatvasinajumi
MY132871A (en) Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
IL134748A0 (en) Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
IL127170A0 (en) Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
LV12262A (lv) Ar arilaminu kondenseti piridini un pirimidini
GR3029561T3 (en) Pyrrolopyrimidines as crf antagonists.
MY146935A (en) 4-(2-BUTYLAMINO-2, 7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-yl) PYRAZOLO-[1,5-a]-1,3,5-TRIAZINE, ITS ENANTIOMERS AND PHARMACEUTICALLY ACCEPTABLE SALTS AS CORTICOTROPIN RELEASING FACTOR RECEPTOR LIGANDS
EP1140929A4 (en) 1H-IMIDAZO 4,5-D] PYRIDAZINE-7-ONES, 3H-IMIDAZO 4,5-C] PYRIDINE-4-ONES AND CORRESPONDING THIONES SUITABLE AS CORTICOLIBERIN RECEPTOR LIGANDS
MXPA03010324A (es) PIRAZINONAS, PIRIDINAS Y PIRIMIDINAS SUBSTITUIDAS COMO LIGANDOS DEL FACTOR DE LIBERACIoN DE CORTICOTROPINA.
WO2002004453A3 (en) PYRROLO[3,4-d]PYRIMIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS
MY141511A (en) Azolo triazines and pyrimidines
MY141976A (en) Azolo triazines and pyrimidines
CA2532925A1 (en) Azolo triazines and pyrimidines
MY141752A (en) Pyrazolotriazines as crf antagonists